LIFESCAPES Selected for AMED's FY2026 'Bridging Research Program'

Key facts

  • LIFESCAPES Selected for AMED's FY2026 'Bridging Research Program'
  • LIFESCAPES Inc. has been selected for the FY2026 'Bridging Research Program' by the Japan Agency for Medical Research and Development (AMED). In collaboration with Hokkaido University and Professor Masahiko Mukano, the company will conduct a physician-led clinical trial evaluating BCI-based neurorehabilitation for severe post-stroke upper limb dysfunction.
  • Source: PR Times
  • Date: June 18, 2026

Direct answer

LIFESCAPES Inc. has been selected for the FY2026 'Bridging Research Program' by the Japan Agency for Medical Research and Development (AMED). In collaboration with Hokkaido University and Professor Masahiko Mukano, the company will conduct a physician-led clinical trial evaluating BCI-based neurorehabilitation for severe post-stroke upper limb dysfunction.

Citation
LIFESCAPES Selected for AMED's FY2026 'Bridging Research Program' (June 18, 2026), PR Times
Source
PR Times
Date
June 18, 2026
LIFESCAPES Inc. has been selected for the FY2026 'Bridging Research Program' by the Japan Agency for Medical Research and Development (AMED). In collaboration with Hokkaido University and Professor Masahiko Mukano, the company will conduct a physician-led clinical trial evaluating BCI-based neurorehabilitation for severe post-stroke upper limb dysfunction.

📋 Article Processing Timeline

  • 📰 Published: June 18, 2026 at 19:30
  • 🔍 Collected: June 18, 2026 at 10:47
  • 🤖 AI Analyzed: June 19, 2026 at 09:48 (23h 0m after Collected)
LIFESCAPES Inc. (Headquarters: Minato-ku, Tokyo; CEO: Junichi Ushiba; hereinafter 'LIFESCAPES') announces that its research and development project utilizing Brain-Computer Interface (BCI) technology has been selected for the Japan Agency for Medical Research and Development (AMED)'s FY2026 'Bridging Research Program'. This project will be implemented as a physician-led clinical trial to evaluate the efficacy and safety of an innovative neurorehabilitation approach for severe upper limb functional impairment following stroke, with Hokkaido University as the supporting institution and Professor Masahiko Mukano of the university serving as the principal investigator.

■ Overview of the Selected R&D Project

Program Name: Japan Agency for Medical Research and Development (AMED) FY2026 'Bridging Research Program'

Project Title: 'Physician-Led Clinical Trial on the Efficacy and Safety of Brain-Computer Interface for Severe Upper Limb Functional Impairment After Stroke'

Supporting Institution: Hokkaido University

Principal Investigator: Professor Masahiko Mukano, Hokkaido University

■ Objectives of the Program

AMED's 'Bridging Research Program' is a research and development support initiative aimed at rapidly translating outstanding research results from universities and other institutions into clinical practice and practical applications (social implementation). The selected project is a physician-led clinical trial evaluating the efficacy and safety of interventions using Brain-Computer Interface (BCI) technology for severe upper limb functional impairment after stroke. By applying BCI technology—which reads brain signals to support rehabilitation—to patients with severe paralysis who have shown limited recovery with conventional rehabilitation approaches, this project aims to establish a new treatment option and improve patients' motor function.

■ Future Outlook

Building on this selection, LIFESCAPES will strengthen collaborations with medical and research institutions, including Hokkaido University, to accelerate the generation of robust scientific evidence and the practical implementation of these technologies in clinical settings. LIFESCAPES will continue to contribute to improving the quality of life for patients with severe paralysis after stroke through the research and development of cutting-edge neurorehabilitation medical devices utilizing BCI technology.

🔗 Related Link (AMED Grant Selection Information)

https://www.amed.go.jp/koubo/03007/01/C_00001.html

■ About LIFESCAPES

LIFESCAPES is a medical device startup originating from Keio University, engaged in the research and development of neurorehabilitation medical devices and related services based on Brain-Machine Interface (BMI) technology. The company aims to address unmet medical needs in the field of central nervous system disorders, particularly upper limb paralysis after stroke, by providing innovative treatment options.

Links

Official Website: https://lifescapes.jp/

Official Facebook: https://www.facebook.com/lifescapes2018

Official LinkedIn: https://www.linkedin.com/company/lifescapes-bci/

Official X: https://x.com/LIFESCAPES_BMI

■ Contact

PR Office: Kimoto (kimoto@mikupr.co.jp)

FAQ

What is LIFESCAPES?

A Keio University-originated medtech startup developing BCI-based neurorehabilitation devices for stroke recovery.

What is the goal of this research?

To evaluate the efficacy and safety of BCI-based rehabilitation for severe upper limb paralysis after stroke.

Where will the research be conducted?

Hokkaido University is the supporting institution, with Prof. Mukano leading the physician-led clinical trial.

What is BCI technology?

Brain-Computer Interface reads brain signals to control external devices, used here to support motor rehabilitation.

Who are the target patients?

Patients with severe upper limb paralysis after stroke, who have limited recovery with conventional therapy.